View More Recent Stories

May 30, 2023 09:00AM Biofrontera Inc. Names Founder and Executive Chairman Hermann Luebbert as Chief Executive Officer
May 15, 2023 09:56AM Biofrontera Inc. (BFRI) Issues US Patent for Photodynamic Therapy Protocol with Reduced Side Effects
May 15, 2023 09:50AM Biofrontera Inc. Announces U.S. Patent Issued for Photodynamic Therapy Protocol with Reduced Side Effects
May 12, 2023 07:30AM Biofrontera Inc. Reports First Quarter 2023 Financial Results and Provides a Business Update
May 12, 2023 07:01AM Biofrontera (BFRI) Announces CEO Resignation
May 12, 2023 07:00AM Biofrontera Inc. Announces Resignation of CEO
May 9, 2023 09:00AM Biofrontera Collaborates with The Skin Cancer Foundation to Raise Awareness of Skin Cancer Prevention
Apr 28, 2023 10:00AM Biofrontera Inc. to Report First Quarter 2023 Financial Results on May 12, 2023
Apr 26, 2023 10:05AM Biofrontera Inc. (BFRI) Announces Last Patient Out in Phase I Trial of Ameluz, Expects Results in Q4
Apr 26, 2023 10:00AM Biofrontera Inc. Announces Last Patient Out in Phase I Study to Evaluate Safety and Tolerability in Treating Actinic Keratosis Using 3 Tubes of Ameluz(R)
Apr 26, 2023 10:00AM Biofrontera Inc. Announces Last Patient Out in Phase I Study to Evaluate Safety and Tolerability in Treating Actinic Keratosis Using 3 Tubes of Ameluz(R)
View More Recent Stories